<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="4469"><DrugName>irbesartan</DrugName><DrugNamesKey><Name id="42767516">Aprovel</Name><Name id="42907358">Avapro</Name><Name id="42886449">Irbetan</Name><Name id="42767515">Karvea</Name><Name id="42756612">irbesartan</Name></DrugNamesKey><DrugSynonyms><Name><Value>BMS-186295</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>irbesartan</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>SR 474436</Value></Name><Name><Value>Karvea</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Aprovel</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>SR-47436</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Irbetan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Avapro</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>138402-11-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26495">Sanofi (pre-1999)</CompanyOriginator><CompaniesPrimary><Company id="1009547">Sanofi SA</Company><Company id="1057390">Handok-Aventis</Company><Company id="26495">Sanofi (pre-1999)</Company><Company id="19898">Shionogi &amp; Co Ltd</Company><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="15134">Bristol-Myers Squibb KK</Company><Company id="26494">Sanofi-Synthelabo</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4469" type="Drug"><TargetEntity id="176436" type="siDrug">Irbesartan</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="1017117" type="Company"><TargetEntity id="4295877685" type="organizationId">Sumitomo Dainippon Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1057390" type="Company"><TargetEntity id="5035526704" type="organizationId">Handok Aventis</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="15134" type="Company"><TargetEntity id="5000271360" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="19898" type="Company"><TargetEntity id="4295876951" type="organizationId">Shionogi &amp; Co Ltd</TargetEntity></SourceEntity><SourceEntity id="26494" type="Company"><TargetEntity id="5000326934" type="organizationId">Sanofi Synthelabo Caraibes SARL</TargetEntity></SourceEntity><SourceEntity id="26495" type="Company"><TargetEntity id="4295866846" type="organizationId">Thales SA</TargetEntity></SourceEntity><SourceEntity id="100" type="ciIndication"><TargetEntity id="10061835" type="MEDDRA"></TargetEntity><TargetEntity id="D003928" type="MeSH"></TargetEntity><TargetEntity id="-271673667" type="omicsDisease"></TargetEntity><TargetEntity id="342" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1559" type="ciIndication"><TargetEntity id="428.0" type="ICD9"></TargetEntity><TargetEntity id="10007559" type="MEDDRA"></TargetEntity><TargetEntity id="239" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"></TargetEntity><TargetEntity id="D006973" type="MeSH"></TargetEntity><TargetEntity id="-369992864" type="omicsDisease"></TargetEntity><TargetEntity id="240" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="788" type="Action"><TargetEntity id="67" type="Mechanism">Angiotensin AT1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00137" type="ciTarget"><TargetEntity id="11815532851853" type="siTarget">Type-1 angiotensin II receptor</TargetEntity><TargetEntity id="719715579" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Hypertension - Netherlands - Aug-1997</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="100">Diabetic nephropathy</Indication><Indication id="178">Hypertension</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1559">Congestive heart failure</Indication></IndicationsSecondary><ActionsPrimary><Action id="788">Angiotensin II AT-1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2659">Cardioprotectant</Action><Action id="2657">Antihypertensive</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-26T08:25:38.000Z</LastModificationDate><ChangeDateLast>2019-02-04T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Irbesartan (Avapro; Aprovel; Irbetan; Karvea) is a long-lasting angiotensin II receptor antagonist developed and launched by &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;, and is now comarketed with &lt;ulink linkID="19898" linkType="Company"&gt;Shionogi &amp;amp; Co&lt;/ulink&gt; and &lt;ulink linkID="1017117" linkType="Company"&gt;Sumitomo Dainippon Pharma&lt;/ulink&gt; (formerly Dainippon Sumitomo Pharma). In the US, the product is indicated for the treatment of hypertension, when used either alone or in combination with other antihypertensive agents, and to reduce the rate of progression of diabetic nephropathy in patients with type 2 diabetes and hypertension [&lt;ulink linkID="1626422" linkType="Reference"&gt;1626422&lt;/ulink&gt;].  In the EU, the product is indicated in adults for the treatment of essential hypertension, and for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen [&lt;ulink linkID="1626428" linkType="Reference"&gt;1626428&lt;/ulink&gt;]. In Japan, the product is indicated for hypertension [&lt;ulink linkID="919926" linkType="Reference"&gt;919926&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Irbesartan was first launched for hypertension in Europe in August 1997 [&lt;ulink linkID="270242" linkType="Reference"&gt;270242&lt;/ulink&gt;], [&lt;ulink linkID="270168" linkType="Reference"&gt;270168&lt;/ulink&gt;]. US launch followed in October 1997 [&lt;ulink linkID="270242" linkType="Reference"&gt;270242&lt;/ulink&gt;]. In July 2008, the product was launched in Japan [&lt;ulink linkID="919926" linkType="Reference"&gt;919926&lt;/ulink&gt;]; Shionogi was to market the drug as Irbetan, while  Sumitomo Dainippon would market it as Avapro [&lt;ulink linkID="907856" linkType="Reference"&gt;907856&lt;/ulink&gt;]. In June 2013, a 200-mg tablet was launched in Japan [&lt;ulink linkID="1437598" linkType="Reference"&gt;1437598&lt;/ulink&gt;], [&lt;ulink linkID="1437660" linkType="Reference"&gt;1437660&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;A US filing for pediatric extensions was submitted in July 2004 [&lt;ulink linkID="598425" linkType="Reference"&gt;598425&lt;/ulink&gt;]; however, the FDA ruled that irbesartan was not efficacious in patients aged between 6 and 16 years [&lt;ulink linkID="669596" linkType="Reference"&gt;669596&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2002, irbesartan was additionally approved for the treatment of diabetic nephropathy in patients with hypertension and type 2 diabetes in Europe [&lt;ulink linkID="456453" linkType="Reference"&gt;456453&lt;/ulink&gt;]; this indication was approved by the FDA in September 2002 [&lt;ulink linkID="464437" linkType="Reference"&gt;464437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was also clinically evaluated for potential label extensions for use in heart failure and atrial fibrillation. In June 2002, the phase III I-PRESERVE study began  to evaluate irbesartan on mortality and morbidity in congestive heart failure [&lt;ulink linkID="935178" linkType="Reference"&gt;935178&lt;/ulink&gt;]; in November 2008, results demonstrated that the drug did not meet its primary endpoint in reducing death or hospitalizations [&lt;ulink linkID="959121" linkType="Reference"&gt;959121&lt;/ulink&gt;]. In March 2003, the phase III ACTIVE-I trial began  to evaluate irbesartan in the reduction of the risk of vascular events such as heart attack, stroke, thromboembolic event or death in patients with atrial fibrillation and  hypertension  [&lt;ulink linkID="935149" linkType="Reference"&gt;935149&lt;/ulink&gt;]; results reported in September 2009 indicated the drug did not meet its primary endpoint of mortality reduction [&lt;ulink linkID="1072228" linkType="Reference"&gt;1072228&lt;/ulink&gt;]. No further development was reported in these indications.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) was previously co-marketing the drug with Sanofi; however, in January 2013, BMS returned its rights to Sanofi [&lt;ulink linkID="1328055" linkType="Reference"&gt;1328055&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15065" linkType="Company"&gt;&lt;/ulink&gt;Sanofi also markets the irbesartan/hydrochlorothiazide (HCTZ) combination product &lt;ulink linkID="24189" linkType="Drug"&gt;CoAprovel&lt;/ulink&gt;, while BMS markets it in the US as &lt;ulink linkID="24189" linkType="Drug"&gt;Avalide&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;The Orange Book lists two US patents for irbesartan. The product patent &lt;ulink linkID="IN2153957" linkType="Patent"&gt;US-05270317&lt;/ulink&gt; was granted a 6-month pediatric extension, and expired March 30, 2012 [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;], [&lt;ulink linkID="1170676" linkType="Reference"&gt;1170676&lt;/ulink&gt;], [&lt;ulink linkID="1224987" linkType="Reference"&gt;1224987&lt;/ulink&gt;]. The formulation patent &lt;ulink linkID="PA184483" linkType="Patent"&gt;US-06342247&lt;/ulink&gt; was also granted a 6-month pediatric extension, and expired in December 2015.&lt;/para&gt;&lt;para&gt;In July 2004, &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt; filed an ANDA with a Paragraph IV certification for a generic version of irbesartan in the US. The filing did not challenge the product patent, but alleged only that the Teva formulation did not infringe US-06342247. Sanofi-Synthelabo and BMS were examining the notice to decide their response [&lt;ulink linkID="553918" linkType="Reference"&gt;553918&lt;/ulink&gt;]. In March 2012, Teva received final FDA approval for its generic irbesartan tablets (75, 150 and 300 mg) [&lt;ulink linkID="1303536" linkType="Reference"&gt;1303536&lt;/ulink&gt;]. In April 2012, Teva launched its generic product following patent expiry; the company was entitled to 180 days marketing exclusivity [&lt;ulink linkID="1276726" linkType="Reference"&gt;1276726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2009, the FDA granted tentative approval to an ANDA from &lt;ulink linkID="15503" linkType="Company"&gt;Cipla&lt;/ulink&gt; for 75, 150 and 300  mg generic irbesartan tablets [&lt;ulink linkID="1049580" linkType="Reference"&gt;1049580&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2010, &lt;ulink linkID="29062" linkType="Company"&gt;Zydus&lt;/ulink&gt; received tentative FDA approval for its generic version of irbesartan tablets (75, 150 and 300 mg) [&lt;ulink linkID="1171006" linkType="Reference"&gt;1171006&lt;/ulink&gt;]; final FDA approval was granted to Zydus in September 2012 [&lt;ulink linkID="1350508" linkType="Reference"&gt;1350508&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; was granted tentative approval of 75, 150 and 300 mg generic versions  [&lt;ulink linkID="1271564" linkType="Reference"&gt;1271564&lt;/ulink&gt;]. In September 2012, Mylan's generic irbesartan was approved and launched in the US [&lt;ulink linkID="1327164" linkType="Reference"&gt;1327164&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt; was granted tentative approval for its generic tablets (75, 150 and 300 mg) [&lt;ulink linkID="1272811" linkType="Reference"&gt;1272811&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, &lt;ulink linkID="22353" linkType="Company"&gt;Apotex&lt;/ulink&gt; received tentative FDA approval for its generic irbesartan tablets (75, 150 and 300 mg) [&lt;ulink linkID="1308545" linkType="Reference"&gt;1308545&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, &lt;ulink linkID="21717" linkType="Company"&gt;Watson Pharmaceuticals&lt;/ulink&gt; received FDA approval for its generic irbesartan tablets (75, 150 and 300 mg); the product was to be launched immediately [&lt;ulink linkID="1331318" linkType="Reference"&gt;1331318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, &lt;ulink linkID="22588" linkType="Company"&gt;Roxane Laboratories&lt;/ulink&gt; was granted final FDA approval for its generic irbesartan tablets; the company began shipment of the product immediately [&lt;ulink linkID="1412084" linkType="Reference"&gt;1412084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2012, Sanofi had launched an authorized generic version of irbesartan [&lt;ulink linkID="1393823" linkType="Reference"&gt;1393823&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;Data exclusivity expired in August 2007 [&lt;ulink linkID="1170676" linkType="Reference"&gt;1170676&lt;/ulink&gt;]. The compound patent expired in the majority of European countries in August 2012, with the exception of the Czech Republic, Hungary, Romania and Slovakia, where it expired in March 2011, with coverage  in Lithuania and Latvia expiring in 2013 (in Lithuania in May 2013). There is no compound patent in force in Spain, Portugal, Finland, Norway, or the majority of Eastern Europe [&lt;ulink linkID="1172270" linkType="Reference"&gt;1172270&lt;/ulink&gt;], [&lt;ulink linkID="1393823" linkType="Reference"&gt;1393823&lt;/ulink&gt;]. Later filed formulation patents expire in the EU in 2016 [&lt;ulink linkID="1084747" linkType="Reference"&gt;1084747&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2009, the EMA's CHMP recommended approval of a Teva generic [&lt;ulink linkID="1028135" linkType="Reference"&gt;1028135&lt;/ulink&gt;], [&lt;ulink linkID="1045387" linkType="Reference"&gt;1045387&lt;/ulink&gt;]. By March 2010, irbesartan generics were available in Spain and Portugal [&lt;ulink linkID="1084747" linkType="Reference"&gt;1084747&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2012, the EMA's CHMP recommended approval of Sabervel, &lt;ulink linkID="1003489" linkType="Company"&gt;Pharmathen&lt;/ulink&gt;'s generic version of irbesartan tablets (75, 150 and 300 mg) in Europe  [&lt;ulink linkID="1263863" linkType="Reference"&gt;1263863&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;The compound patent expired  in Japan in March 2016, and the formulation patent expires in 2021; regulatory exclusivity expired in April 2016 [&lt;ulink linkID="1084747" linkType="Reference"&gt;1084747&lt;/ulink&gt;], [&lt;ulink linkID="1393823" linkType="Reference"&gt;1393823&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, a generic version of Irbertan was launched in Japan [&lt;ulink linkID="2087305" linkType="Reference"&gt;2087305&lt;/ulink&gt;]; in that month, Sumitomo Dainippon launched an authorized generic version of Avapro tablets DSPB [&lt;ulink linkID="2078738" linkType="Reference"&gt;2078738&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By December 2016, generic competition had begun in Japan [&lt;ulink linkID="1907559" linkType="Reference"&gt;1907559&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In March 2019, &lt;ulink linkID="1030351" linkType="Company"&gt;Zhejiang Tianyu Pharmaceutical&lt;/ulink&gt; filed an ANDA application for its generic version of  irbesartan tablet in China   [&lt;ulink linkID="2124883" linkType="Reference"&gt;2124883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2019,&lt;ulink linkID="1072650" linkType="Company"&gt; Hunan Jiudian Pharmaceutical&lt;/ulink&gt; filed an ANDA application for its generic version of  irbesartan tablet in China [&lt;ulink linkID="2107483" linkType="Reference"&gt;2107483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;The Canadian composition of matter patent expired in March 2011 [&lt;ulink linkID="1264186" linkType="Reference"&gt;1264186&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, Sanofi noted that generic versions of the drug had been launched in markets outside the US and Europe [&lt;ulink linkID="1907559" linkType="Reference"&gt;1907559&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;US launch for hypertension took place in October 1997 [&lt;ulink linkID="270242" linkType="Reference"&gt;270242&lt;/ulink&gt;]. A US filing for pediatric extensions was submitted in July 2004 [&lt;ulink linkID="598425" linkType="Reference"&gt;598425&lt;/ulink&gt;]; however, the FDA ruled that irbesartan was not efficacious in patients between 6 and 16 years old [&lt;ulink linkID="669596" linkType="Reference"&gt;669596&lt;/ulink&gt;]. By March 2005, a reduced-mass tablet formulation had been approved in the US [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;], [&lt;ulink linkID="598425" linkType="Reference"&gt;598425&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2001, BMS and Sanofi-Synthelabo submitted an sNDA for the use of irbesartan for indications other than hypertension. The supplemental findings were based on positive results from the PRIME research program, which showed that irbesartan protected patients with hypertension and type 2 diabetes against the progression of kidney disease at early and late stages [&lt;ulink linkID="419127" linkType="Reference"&gt;419127&lt;/ulink&gt;]. Priority review had been granted by the FDA by September 2001 [&lt;ulink linkID="421268" linkType="Reference"&gt;421268&lt;/ulink&gt;]. In January 2002, the FDA's cardiovascular and renal drugs advisory committee voted six to five against the approval of irbesartan in diabetic nephropathy. At this time, the group was due to meet with the FDA in early February 2002 when the final decision was to be made [&lt;ulink linkID="437158" linkType="Reference"&gt;437158&lt;/ulink&gt;]; however, before the scheduled meeting BMS and Sanofi withdrew the sNDA, stating that more time was needed to address fully remaining questions on the file prior to resubmission [&lt;ulink linkID="439880" linkType="Reference"&gt;439880&lt;/ulink&gt;], [&lt;ulink linkID="440329" linkType="Reference"&gt;440329&lt;/ulink&gt;], [&lt;ulink linkID="440812" linkType="Reference"&gt;440812&lt;/ulink&gt;]. In March 2002, Sanofi-Synthelabo resubmitted the sNDA to the FDA [&lt;ulink linkID="452906" linkType="Reference"&gt;452906&lt;/ulink&gt;], and the FDA granted approval in September 2002 [&lt;ulink linkID="464437" linkType="Reference"&gt;464437&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In August 1997, the drug was approved in the EU [&lt;ulink linkID="1626457" linkType="Reference"&gt;1626457&lt;/ulink&gt;]. Irbesartan was launched for hypertension in the Netherlands in August 1997 [&lt;ulink linkID="270242" linkType="Reference"&gt;270242&lt;/ulink&gt;], [&lt;ulink linkID="270168" linkType="Reference"&gt;270168&lt;/ulink&gt;].  In September 1997, the product was  launched  in Germany and the UK [&lt;ulink linkID="268231" linkType="Reference"&gt;268231&lt;/ulink&gt;]. By September 2006, launch had occurred in Ireland, Norway, Finland and Denmark [&lt;ulink linkID="801347" linkType="Reference"&gt;801347&lt;/ulink&gt;]. By March 2012, the product had been launched in Greece, Spain, Italy [&lt;ulink linkID="1269852" linkType="Reference"&gt;1269852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 1998, the drug was launched in Switzerland [&lt;ulink linkID="1545365" linkType="Reference"&gt;1545365&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2005, a reduced-mass tablet formulation had been launched in the EU [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;], [&lt;ulink linkID="598425" linkType="Reference"&gt;598425&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In October 2002, irbesartan was filed for hypertension in Japan and by November 2004 Shionogi was in dose discussions with the Japanese regulatory authorities [&lt;ulink linkID="503537" linkType="Reference"&gt;503537&lt;/ulink&gt;], [&lt;ulink linkID="512223" linkType="Reference"&gt;512223&lt;/ulink&gt;], [&lt;ulink linkID="545339" linkType="Reference"&gt;545339&lt;/ulink&gt;], [&lt;ulink linkID="574993" linkType="Reference"&gt;574993&lt;/ulink&gt;]. In May 2005, negotiations with regulatory bodies regarding additional data were nearing completion [&lt;ulink linkID="619119" linkType="Reference"&gt;619119&lt;/ulink&gt;]. A filing was resubmitted at the end of 2006, after it was supplemented with additional studies at the request of the Japanese authorities [&lt;ulink linkID="884729" linkType="Reference"&gt;884729&lt;/ulink&gt;]. Approval was granted for hypertension in April 2008 (50 and 100 mg), with Shionogi to market the drug as Irbetan and Sumitomo Dainippon to market it as Avapro [&lt;ulink linkID="907856" linkType="Reference"&gt;907856&lt;/ulink&gt;]; Sumitomo Dainippon launched irbesartan in July 2008 [&lt;ulink linkID="919926" linkType="Reference"&gt;919926&lt;/ulink&gt;]; later that month, Shionogi had launched the drug in Japan [&lt;ulink linkID="929382" linkType="Reference"&gt;929382&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;A 200-mg doseage formulation was approved in March 2013 [&lt;ulink linkID="1399015" linkType="Reference"&gt;1399015&lt;/ulink&gt;]. In June 2013, the 200-mg tablet was launched in Japan [&lt;ulink linkID="1437598" linkType="Reference"&gt;1437598&lt;/ulink&gt;], [&lt;ulink linkID="1437660" linkType="Reference"&gt;1437660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;By November 2011, the drug had been launched in China [&lt;ulink linkID="1240651" linkType="Reference"&gt;1240651&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By December 2008, the product had been launched in Canada [&lt;ulink linkID="1009655" linkType="Reference"&gt;1009655&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By March 2012, the product was available in Brazil [&lt;ulink linkID="1269852" linkType="Reference"&gt;1269852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, the product was available in   Mexico [&lt;ulink linkID="1269852" linkType="Reference"&gt;1269852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, the product was available in Argentina [&lt;ulink linkID="1269852" linkType="Reference"&gt;1269852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2012, the product had been launched in Puerto Rico [&lt;ulink linkID="1393823" linkType="Reference"&gt;1393823&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent State&lt;/subtitle&gt;In September 1997, approval was granted in Russia for hypertension [&lt;ulink linkID="262802" linkType="Reference"&gt;262802&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In  July 1999, irbesartan was approved in Taiwan for hypertension and diabetic nephropathy; it was assumed that launch took place shortly after [&lt;ulink linkID="1517010" linkType="Reference"&gt;1517010&lt;/ulink&gt;], [&lt;ulink linkID="1516978" linkType="Reference"&gt;1516978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2007, the drug had been launched in Korea [&lt;ulink linkID="933502" linkType="Reference"&gt;933502&lt;/ulink&gt;]. It has been reported that the drug was available through &lt;ulink linkID="19986" linkType="Company"&gt;Handok&lt;/ulink&gt;, presumably through the joint venture &lt;ulink linkID="1057390" linkType="Company"&gt;Handok-Aventis&lt;/ulink&gt; [&lt;ulink linkID="1137982" linkType="Reference"&gt;1137982&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2012, the product was available in Australia [&lt;ulink linkID="1269852" linkType="Reference"&gt;1269852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The drug's label contains a black box warning regarding the risk of fetal toxicity [&lt;ulink linkID="1626422" linkType="Reference"&gt;1626422&lt;/ulink&gt;]. In July 2010, data published from a meta-analysis suggested that angiotensin II antagonists may be associated with a modestly increased risk of cancer [&lt;ulink linkID="1107860" linkType="Reference"&gt;1107860&lt;/ulink&gt;]. In June 2011, the FDA concluded that, following a review of data involving more than 155,000 patients, treatment with angiotensin II antagonists does not increase the risk of cancer [&lt;ulink linkID="1197170" linkType="Reference"&gt;1197170&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In February 2006, a non-randomized, open-label, phase IV trial (&lt;ulink linkID="16117" linkType="Protocol"&gt;NCT00362037&lt;/ulink&gt;; I SELECT) was initiated in Egypt in hypertensive subjects (expected n = 418) with left ventricular hypertrophy. The subjects were to receive daily irbesartan (150 or 300 mg) or CoAprovel (irbesartan/HCTZ 300/12.5 mg). The primary endpoints were reduction in blood pressure to target values and reduction in left ventricular hypertrophy at 36 weeks. This study was completed in September 2008 [&lt;ulink linkID="940984" linkType="Reference"&gt;940984&lt;/ulink&gt;]. In May 2011, results were published. In an intent-to-treat population (n = 214), irbesartan induced a significant mean reduction (18%) in left ventricular mass compared to baseline. Irbesartan 150 mg reduced the mean systolic and diastolic BP to 122.7 and 78.1 mmHg, respectively,     compared to 153 and 95.7 mmHg at baseline.  Irbesartan 300 mg reduced the mean systolic and diastolic BP to 129.0 and 80.9 mmHg     compared to 157.5 and 97.8 mmHg at baseline. &lt;ulink linkID="24189" linkType="Drug"&gt;&lt;/ulink&gt;CoAprovel reduced the mean systolic and diastolic BP to 132.2 and 82.0 mmHg     compared to 164.5 and 98.6 mmHg at baseline [&lt;ulink linkID="1197001" linkType="Reference"&gt;1197001&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In February 2006, a non-randomized, open-label, phase IV trial (&lt;ulink linkID="10128" linkType="Protocol"&gt;NCT00362258&lt;/ulink&gt;; I PREVENT) was initiated in Egypt in hypertensive diabetic subjects (expected n = 1081). The subjects were to receive daily irbesartan (150 or 300 mg) or CoAprovel (irbesartan/HCTZ 300/12.5 mg). The primary endpoint was achievement of the blood pressure target of 130/80 mmHg. The study was completed in October 2008 [&lt;ulink linkID="940971" linkType="Reference"&gt;940971&lt;/ulink&gt;]. In December 2010, results were published. Treatment with irbesartan (150 mg) for 16 weeks led to a significant mean reduction of SBP of 6.63 mmHg; a mean reduction of 24.87 mmHg was seen for irbesartan 300 mg. For CoAprovel, there was a mean reduction of 29.53 mmHg [&lt;ulink linkID="1182254" linkType="Reference"&gt;1182254&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, a non-randomized, open-label, phase IV trial (&lt;ulink linkID="16112" linkType="Protocol"&gt;NCT00335673&lt;/ulink&gt;; I SAVE) was initiated in Egypt in subjects (expected n = 1754) with mild to moderate hypertension. The subjects were to receive daily irbesartan (150 or 300 mg) or CoAprovel (irbesartan/HCTZ 300/12.5 mg). The primary endpoint was reduction in blood pressure to target values. The study was completed in November 2006 [&lt;ulink linkID="940981" linkType="Reference"&gt;940981&lt;/ulink&gt;]. Results were published in December 2010. Among the ITT population, 93.2% of patients treated with 150 mg irbesartan experienced reduction in blood pressure; 95.3% experienced reduction in blood pressure at 300 mg [&lt;ulink linkID="1182207" linkType="Reference"&gt;1182207&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, a randomized, double-blind, active-control phase IV trial (&lt;ulink linkID="15441" linkType="Protocol"&gt;NCT00110422&lt;/ulink&gt;; CV131-186; I-RESPOND) was initiated in hypertensive subjects (expected n = 400) with metabolic syndrome in France, Germany, Italy, Norway, Russia and Spain. The subjects were to receive irbesartan (150 mg titrated to 300 mg po qd) or HCTZ (12.5 mg titrated to 25 mg po qd) for 28 weeks. The primary endpoint was change from baseline in insulin resistance by week 16. The study had been completed by June 2008 [&lt;ulink linkID="940988" linkType="Reference"&gt;940988&lt;/ulink&gt;]. Data were published in January 2010. At week 16, neither irbesartan or HCTZ had an effect on insulin resistance or beta-cell function, and no differences between irbesartan and HCTZ with respect to glucose metabolism were observed to 28 weeks. However, irbesartan induced beneficial changes in high-sensitivity-C-reactive protein (irbesartan: −5.5; HCTZ + 19.9) and in urinary albumin/creatinine ratio (irbesartan: −13%; HCTZ + 9%) compared with HCTZ despite a similar decrease in blood pressure in both treatment groups [&lt;ulink linkID="1206809" linkType="Reference"&gt;1206809&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Atrial fibrillation and hypertension&lt;/subtitle&gt;In June 2003, the 9000-patient, multicenter double-blind, placebo-controlled, phase III ACTIVE-I (&lt;ulink linkID="4430" linkType="Protocol"&gt;NCT00249795&lt;/ulink&gt;; EFC49121) study began, to evaluate 300 mg irbesartan once daily  in the reduction of the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event or death during  3 years of follow-up in patients with atrial fibrillation and with a systolic blood pressure of at least 110 mmHg associated with at least one major risk of vascular events because they were already enrolled into the ACTIVE-A or ACTIVE-W trials  [&lt;ulink linkID="935149" linkType="Reference"&gt;935149&lt;/ulink&gt;]; by December 2008, ACTIVE-W had been terminated [&lt;ulink linkID="989413" linkType="Reference"&gt;989413&lt;/ulink&gt;].  In September 2009, results from the ACTIVE clinical program were presented at the European Society of Cardiology meeting in Barcelona, Spain. The program consisted of three component trials, ACTIVE-W (a non-inferiority comparison of &lt;ulink linkID="2836" linkType="Drug"&gt;clopidogrel&lt;/ulink&gt; plus aspirin versus &lt;ulink linkID="44375" linkType="Drug"&gt;warfarin&lt;/ulink&gt; anticoagulation therapy); ACTIVE-A (a double-blind comparison of clopidogrel plus aspirin versus aspirin monotherapy in patients who could not be treated with an oral anticoagulant) and ACTIVE-I. In total, 9016 patients participated in ACTIVE-I. Data showed that the primary endpoints of the study were not met. Irbesartan did not delay the first occurence of any component of the composite of heart attack, stroke or death over 4.5 years, however there was a non-significant trend in favor of irbesartan over placebo, mainly as a result of a 14% reduction in heart failure hospitalizations. Observations from a post hoc analysis suggested that the most common complication in the irbesartan group was heart failure rather than stroke. Furthermore, there was a reduction in strokes in the irbesartan group of up to 40% when primary hemorrhagic and secondary transformation of ischemic stroke were considered together. Overall, ACTIVE-I suggested that irbesartan did not provide additional therapeutic benefit in patients with atrial fibrillation who were well controlled on current therapy [&lt;ulink linkID="1072228" linkType="Reference"&gt;1072228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Congestive heart failure&lt;/subtitle&gt;In June 2002, the  placebo-controlled I-PRESERVE phase III study (&lt;ulink linkID="4577" linkType="Protocol"&gt;NCT00095238&lt;/ulink&gt;; CV131-148) began,  to evaluate irbesartan in the reduction of mortality and cardiovascular morbidity in 4500 patients with congestive heart failure and preserved systolic function on top of existing therapies [&lt;ulink linkID="465262" linkType="Reference"&gt;465262&lt;/ulink&gt;], [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;], [&lt;ulink linkID="935178" linkType="Reference"&gt;935178&lt;/ulink&gt;].  In November 2008, results were presented at the AHA Scientific Sessions in New Orleans, LA.  The drug did not meet its primary endpoint in reducing death or CV hospitalizations, nor did it significantly reduce any pre-specified secondary endpoints compared to placebo. During a mean follow-up of 49.5 months, the primary outcome (death or hospitalization) occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00) [&lt;ulink linkID="959121" linkType="Reference"&gt;959121&lt;/ulink&gt;], [&lt;ulink linkID="970289" linkType="Reference"&gt;970289&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal disease in hypertensive diabetics&lt;/subtitle&gt;The PRIME program consisted of two trials:  IRMA 2 (&lt;ulink linkID="3376" linkType="Protocol"&gt;NCT00317915&lt;/ulink&gt;) in hypertensive patients with type 2 diabetes and microalbuminuria, and IDNT in hypertensive patients with diabetic neuropathy. IRMA 2 was a 2-year multicenter, randomized, double-blind, placebo-controlled study of 590 patients aged 30 to 70 years, which assessed the effects of irbesartan compared to other proven antihypertensive treatments in slowing the progression of diabetic renal disease in hypertensive patients with type 2 diabetes and early-stage kidney disease. IDNT was a multicenter, double-blind, placebo-controlled study of 1715 patients aged 30 to 70 years, which assessed the effect of irbesartan versus amlodipine and other proven antihypertensive treatments on the worsening of diabetic renal disease or all-cause mortality in hypertensive patients with type 2 diabetes and late-stage kidney disease. In June 2001, Sanofi presented data from IRMA 2 and IDNT at the 11th Annual European Society of Hypertension Meeting in Milan, Italy. In the IRMA 2 trial, 300 mg of irbesartan once daily demonstrated a 70% relative risk reduction for the progression from early to later-stage kidney disease (diabetic nephropathy) compared with patients who did not receive irbesartan. Analyses showed that treating 10 patients with hypertension and type 2 diabetes with 300 mg irbesartan daily for 2 years would prevent one patient from developing diabetic nephropathy. In IDNT, irbesartan demonstrated a 20% relative risk reduction in the primary endpoint (progression to doubling of serum creatinine, end-stage renal disease or all-cause mortality) versus control. Irbesartan further demonstrated a 23% relative risk reduction in the primary endpoint versus &lt;ulink linkID="2500" linkType="Drug"&gt;amlodipine&lt;/ulink&gt;. Analyses showed that treating 15 patients with hypertension and type 2 diabetes with irbesartan for 3 years, compared to not receiving irbesartan therapy, would prevent one patient from worsening kidney function, kidney failure or death  [&lt;ulink linkID="413550" linkType="Reference"&gt;413550&lt;/ulink&gt;], [&lt;ulink linkID="419127" linkType="Reference"&gt;419127&lt;/ulink&gt;], [&lt;ulink linkID="475452" linkType="Reference"&gt;475452&lt;/ulink&gt;], [&lt;ulink linkID="422562" linkType="Reference"&gt;422562&lt;/ulink&gt;], [&lt;ulink linkID="426765" linkType="Reference"&gt;426765&lt;/ulink&gt;], [&lt;ulink linkID="427382" linkType="Reference"&gt;427382&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;A new analysis of IDNT was presented at the 23rd Congress of the European Society of Cardiology, Sweden in September 2001. When compared to amlodipine and a control group of antihypertensive treatments, the analysis of combined mortality and morbidity events for both renal and cardiovascular endpoints showed a significant 16% risk reduction in favor of irbesartan, compared with both the control and amlodipine groups [&lt;ulink linkID="420941" linkType="Reference"&gt;420941&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Essential hypertension&lt;/subtitle&gt;The antihypertensive effects of irbesartan were examined in seven major placebo-controlled 8- to 12-week trials in patients with baseline diastolic blood pressures of 95 mmHg to 110 mmHg, which included 1915 patients randomized to irbesartan (1 to 900 mg) and 611 patients randomized to placebo. Once-daily doses of 150 mg and 300 mg provided statistically and clinically significant decreases in systolic and diastolic blood pressure with trough (24 h post-dose) effects after 6 to 12 weeks of treatment compared to placebo, of about 8 to 10/5 to 6 mmHg and  to 12/5 to 8 mmHg, respectively. No further increase in effect was seen at dosages greater than 300 mg. Once-daily administration of therapeutic doses of irbesartan gave peak effects at around 3 to 6 h and, in one ambulatory blood pressure monitoring study, again around 14 h. This was seen with both once-daily and twice-daily dosing. Trough-to-peak ratios for systolic and diastolic response were generally between 60% to 70%. In a continuous ambulatory blood pressure monitoring study, once-daily dosing with 150 mg gave trough and mean 24-h responses similar to those observed in patients receiving twice-daily dosing at the same total daily dose. There was essentially no change in average heart rate in irbesartan-treated patients [&lt;ulink linkID="481713" linkType="Reference"&gt;481713&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were presented at the 1st International Symposium on Angiotensin II Antagonism in London, UK in 1997 which demonstrated that 300 mg irbesartan was more effective than 100 mg &lt;ulink linkID="3517" linkType="Drug"&gt;losartan&lt;/ulink&gt; at lowering blood pressure over an 8-week period. The double-blind, placebo-controlled study involved 567 patients at 41 sites. In this period, irbesartan decreased diastolic and systolic blood pressures by 3.1 mmHg and 5.1 mmHg, respectively [&lt;ulink linkID="270242" linkType="Reference"&gt;270242&lt;/ulink&gt;], [&lt;ulink linkID="270171" linkType="Reference"&gt;270171&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sanofi has stated that irbesartan has bioavailability of 60 to 80%, and thus need only be given once daily [&lt;ulink linkID="266210" linkType="Reference"&gt;266210&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;In February 2017, a single arm, non randomized, uncontrolled study (&lt;ulink linkID="286993" linkType="Protocol"&gt;UMIN000025949&lt;/ulink&gt;) began to evaluate irbesartan on psoriasis patients complicated with hypertension. At that time, the study was assumed to be terminated [&lt;ulink linkID="1898754" linkType="Reference"&gt;1898754&lt;/ulink&gt;].                &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In isolated rabbit aorta, irbesartan inhibited angiotensin II-induced contractions with an IC50 value of 4 nM [&lt;ulink linkID="198767" linkType="Reference"&gt;198767&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-11-16T00:00:00.000Z</StatusDate><Source id="1240651" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26495">Sanofi (pre-1999)</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-11-24T00:00:00.000Z</StatusDate><Source id="270242" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-07-28T00:00:00.000Z</StatusDate><Source id="929382" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-03-15T00:00:00.000Z</StatusDate><Source id="1545365" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-06-30T00:00:00.000Z</StatusDate><Source id="1009644" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-04-30T00:00:00.000Z</StatusDate><Source id="933502" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-03-15T00:00:00.000Z</StatusDate><Source id="1545365" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-09-27T00:00:00.000Z</StatusDate><Source id="1393823" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1516978" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1516978" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-07-01T00:00:00.000Z</StatusDate><Source id="919926" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-09-21T00:00:00.000Z</StatusDate><Source id="1411596" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1057390">Handok-Aventis</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-10-01T00:00:00.000Z</StatusDate><Source id="1137982" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-29T00:00:00.000Z</StatusDate><Source id="1009652" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26495">Sanofi (pre-1999)</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-11-24T00:00:00.000Z</StatusDate><Source id="270242" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-03-21T00:00:00.000Z</StatusDate><Source id="1384544" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GR">Greece</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="FI">Finland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1328055" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15134">Bristol-Myers Squibb KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-07-24T00:00:00.000Z</StatusDate><Source id="680123" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-30T00:00:00.000Z</StatusDate><Source id="935178" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-09-15T00:00:00.000Z</StatusDate><Source id="268231" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-04-30T00:00:00.000Z</StatusDate><Source id="481713" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-12-29T00:00:00.000Z</StatusDate><Source id="1009655" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><Source id="413342" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-09-30T00:00:00.000Z</StatusDate><Source id="268231" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-09-30T00:00:00.000Z</StatusDate><Source id="268231" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-08-31T00:00:00.000Z</StatusDate><Source id="270242" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-11-24T00:00:00.000Z</StatusDate><Source id="270242" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-09-16T00:00:00.000Z</StatusDate><Source id="262802" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-08T00:00:00.000Z</StatusDate><Source id="1269852" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-30T00:00:00.000Z</StatusDate><Source id="801347" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-09-27T00:00:00.000Z</StatusDate><Source id="1393823" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-07-26T00:00:00.000Z</StatusDate><Source id="1517010" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-07-26T00:00:00.000Z</StatusDate><Source id="1517010" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-03-15T00:00:00.000Z</StatusDate><Source id="1545365" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-03-15T00:00:00.000Z</StatusDate><Source id="1545365" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-08-16T00:00:00.000Z</StatusDate><Source id="419127" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-03-01T00:00:00.000Z</StatusDate><Source id="399945" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-08-16T00:00:00.000Z</StatusDate><Source id="419127" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-08-27T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-10-04T00:00:00.000Z</StatusDate><Source id="220786" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication><Source id="176815" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication><Source id="165739" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15134">Bristol-Myers Squibb KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-06-23T00:00:00.000Z</StatusDate><Source id="328887" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15134">Bristol-Myers Squibb KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication><Source id="208536" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-09-18T00:00:00.000Z</StatusDate><Source id="464437" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-11-12T00:00:00.000Z</StatusDate><Source id="469964" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="CA">Canada</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-09-11T00:00:00.000Z</StatusDate><Source id="465262" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-09-11T00:00:00.000Z</StatusDate><Source id="465262" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-09-11T00:00:00.000Z</StatusDate><Source id="465262" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication><Source id="176815" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15134">Bristol-Myers Squibb KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-10-31T00:00:00.000Z</StatusDate><Source id="469783" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-06-23T00:00:00.000Z</StatusDate><Source id="328887" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-07-24T00:00:00.000Z</StatusDate><Source id="680123" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-29T00:00:00.000Z</StatusDate><Source id="785932" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-29T00:00:00.000Z</StatusDate><Source id="785932" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017117">Sumitomo Dainippon Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-04-16T00:00:00.000Z</StatusDate><Source id="907856" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-04-16T00:00:00.000Z</StatusDate><Source id="907856" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-11-24T00:00:00.000Z</StatusDate><Source id="270242" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-27T00:00:00.000Z</StatusDate><Source id="456453" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-06-27T00:00:00.000Z</StatusDate><Source id="456453" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-08-20T00:00:00.000Z</StatusDate><Source id="555709" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-10-08T00:00:00.000Z</StatusDate><Source id="265424" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-09-18T00:00:00.000Z</StatusDate><Source id="464437" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-08-20T00:00:00.000Z</StatusDate><Source id="555709" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-11-12T00:00:00.000Z</StatusDate><Source id="469964" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-10-08T00:00:00.000Z</StatusDate><Source id="265424" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-08-27T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-10-04T00:00:00.000Z</StatusDate><Source id="220786" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-10-04T00:00:00.000Z</StatusDate><Source id="220786" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00137"><Name>Angiotensin II AT-1 receptor</Name><SwissprotNumbers><Swissprot>O35210</Swissprot><Swissprot>O77590</Swissprot><Swissprot>P25095</Swissprot><Swissprot>P25104</Swissprot><Swissprot>P29089</Swissprot><Swissprot>P29754</Swissprot><Swissprot>P29755</Swissprot><Swissprot>P30555</Swissprot><Swissprot>P30556</Swissprot><Swissprot>P32303</Swissprot><Swissprot>P33396</Swissprot><Swissprot>P34976</Swissprot><Swissprot>P35373</Swissprot><Swissprot>P43240</Swissprot><Swissprot>P79785</Swissprot><Swissprot>Q9GLN9</Swissprot><Swissprot>Q9WV26</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2116337" linkType="reference" linkID="2116337"&gt;2116337&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2150291" linkType="reference" linkID="2150291"&gt;2150291&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="20268">Sumitomo Chemical Co Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20993">Yuyu Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)c4ccccc4c5[nH]nnn5</Smiles></StructureSmiles><Deals><Deal id="109084" title="Dainippon and BMS to cross-license irbesartan and SM-11355 in Japan"></Deal><Deal id="112950" title="sanofi aventis and Bristol-Myers Squibb to codevelop clopidogrel formulations and Avapro/Avalide worldwide"></Deal><Deal id="119257" title="Yuyu to co-promote sanofi-aventis's irbesartan in Korea"></Deal><Deal id="189152" title="Irbesartan for hypertension, cross-licensed for SM-11355 for hepatocellular carcinoma in Japan"></Deal></Deals><PatentFamilies><PatentFamily id="1001962" number="IN-00191958" title="An improved process for preparation of form a of irbesartan"></PatentFamily><PatentFamily id="1011348" number="CN-101785858" title="A pharmaceutical composition containing isosorbide mononitrate for treating hypertension"></PatentFamily><PatentFamily id="1014013" number="WO-2006103068" title="A synthesis of 4-bromomethyl-2'-formylbiphenyl and 4-bromomethyl-2'-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists"></PatentFamily><PatentFamily id="1034481" number="KR-2009107960" title="Pharmaceutical preparation for treating cardiovascular disease."></PatentFamily><PatentFamily id="1046201" number="WO-2012137152" title="Method for preparing formamide compounds"></PatentFamily><PatentFamily id="108100" number="WO-2007017469" title="Process for preparing an angiotensin II receptor antagonist"></PatentFamily><PatentFamily id="1082859" number="CN-100418962" title="Technique for synthesizing irbesartan"></PatentFamily><PatentFamily id="1088570" number="WO-2006067215" title="Intermediate compounds for the preparation of angiotensin II receptor antagonists"></PatentFamily><PatentFamily id="1103561" number="WO-2006089927" title="Method for obtaining a pharmaceutically active compound (irbesartan) and its synthesis intermediate"></PatentFamily><PatentFamily id="1116612" number="CN-102309456" title="Irbesartan sodium micro composite powder and tablets and preparation method thereof"></PatentFamily><PatentFamily id="1118400" number="CN-102491970" title="Synthetic method for irbesartan"></PatentFamily><PatentFamily id="1119453" number="IN-200701011" title="Improved process for preparation of irbesartan intermediate"></PatentFamily><PatentFamily id="1141657" number="WO-2005051929" title="Conversion of aromatic nitriles into tetrazoles"></PatentFamily><PatentFamily id="1142273" number="WO-2006011859" title="Preparation of hydrochloride salts of tetrazole derivative"></PatentFamily><PatentFamily id="1154115" number="CN-01270711" title="Aminochlorodipin, irbesartan compound preparation"></PatentFamily><PatentFamily id="1177771" number="US-20080014187" title="Compositions and methods for treating hypertension and inflammation"></PatentFamily><PatentFamily id="117990" number="CZ-00016810" title="Pharmaceutical composition for oral administration containing irbesartan as active substance and being free of surfactant"></PatentFamily><PatentFamily id="1220157" number="WO-2008101375" title="A gastric retentive sustained-release pharmaceutical composition comprising irbesartan"></PatentFamily><PatentFamily id="1231072" number="CN-100413853" title="Synthetic intermediate of irbesartan, preparation method and use thereof"></PatentFamily><PatentFamily id="124273" number="WO-2004089938" title="A novel crystalline form of irbesartan"></PatentFamily><PatentFamily id="1255907" number="CN-101757004" title="A novel compound hypertension-resisting preparation"></PatentFamily><PatentFamily id="1257279" number="CN-101564536" title="Sustained-and-controlled release preparation of pharmaceutical combination for treating hypertension"></PatentFamily><PatentFamily id="1287661" number="EP-01145711" title="Flash-melt oral dosage formulation"></PatentFamily><PatentFamily id="1290324" number="WO-2005113518" title="Process for preparing irbesartan"></PatentFamily><PatentFamily id="130441" number="WO-00037075" title="Combination of an AT1 angiotensin II receptor antagonist and an immunosuppressant"></PatentFamily><PatentFamily id="1309647" number="WO-2008041957" title="Method for producing pure crystalline form of 2-N-butyl-3-((2-(1H-tetrazole-5-yl)(1,1'-biphenyl)-4-methyl)-1,3-diazapspiro(4,4')non-1-en-4-one"></PatentFamily><PatentFamily id="1310006" number="WO-2006097121" title="Method for producing biphenyl-tetrazole compounds"></PatentFamily><PatentFamily id="1317709" number="WO-2006067601" title="Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation"></PatentFamily><PatentFamily id="1339063" number="JP-04974255" title="The compounding agent of an angiotensin ii receptor antagonist"></PatentFamily><PatentFamily id="1341506" number="CN-102432558" title="Method for synthesizing irbesartan and intermediate thereof"></PatentFamily><PatentFamily id="1384041" number="WO-00002556" title="Use of a pharmaceutical composition containing, in combination, an antagonist of the angiotensin II AT1 receptors and indomethacin for making a medicine treating chronic glomerulonephritis."></PatentFamily><PatentFamily id="1384557" number="WO-2008125388" title="Pharmaceutical compositions comprising irbesartan"></PatentFamily><PatentFamily id="1391037" number="RU-02394564" title="Method of optimising functional reactivity of cardio-vascular system in case of crisis course of arterial hypertension with disturbance of glucose tolerance"></PatentFamily><PatentFamily id="1409227" number="CN-101966187" title="Compound preparation curing hypertension and containing amlodipine and irbesartan"></PatentFamily><PatentFamily id="1413048" number="JP-05421945" title="Pharmaceutical composition containing an irbesartan, an amlodipine, or its salt"></PatentFamily><PatentFamily id="143701" number="WO-2007074399" title="Process for the preparation of tetrazolyl compounds"></PatentFamily><PatentFamily id="1440084" number="WO-2006125592" title="Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl)methyl)-imidazole, dihydroimidazole or benzimidazole derivatives"></PatentFamily><PatentFamily id="1440776" number="WO-2007020659" title="A process for the preparation of irbesartan form A"></PatentFamily><PatentFamily id="1442147" number="WO-2008087401" title="Sulfate salts of irbesartan and their preparation and pharmaceutical compositions"></PatentFamily><PatentFamily id="1458441" number="CN-101618215" title="A medicinal composition containing calcium antagonist, AT-II receptor antagonist and statins"></PatentFamily><PatentFamily id="1466323" number="WO-2011024154" title="Use of irbesartan for the preparation of a medicament for the prevention of hospitalization for heart failure."></PatentFamily><PatentFamily id="148627" number="EP-01275391" title="Pharmaceutical compositions containing irbesartan and a diuretic"></PatentFamily><PatentFamily id="1531707" number="EP-01555260" title="Phenyltetrazole compounds"></PatentFamily><PatentFamily id="1538527" number="CN-102219779" title="Synthesis method of irbesartan"></PatentFamily><PatentFamily id="1541609" number="CN-01493284" title="Composite blood pressure reducing agent containing indapamide and angiotensin II acceptor antagonist"></PatentFamily><PatentFamily id="1544746" number="WO-2006046043" title="Process for the preparation of irbesartan hydrochloride"></PatentFamily><PatentFamily id="1550613" number="CN-101327213" title="Irbesartan and hydrochlorothiazide pharmaceutical composition and preparing method thereof"></PatentFamily><PatentFamily id="1551910" number="CN-101756975" title="A compound preparation for treating hypertension"></PatentFamily><PatentFamily id="158578" number="IN-200701478" title="Pharmaceutical compositions comprising solid dispersion of irbesartan or salt thereof"></PatentFamily><PatentFamily id="1586009" number="WO-2005051943" title="Processes for the preparation of highly pure irbesartan"></PatentFamily><PatentFamily id="1586527" number="WO-2006001026" title="Irbesartan polymorphs"></PatentFamily><PatentFamily id="1589006" number="WO-2007052301" title="Process for the preparation of irbesartan"></PatentFamily><PatentFamily id="1622415" number="WO-2007099555" title="Pharmaceutical compositions containing irbesartan"></PatentFamily><PatentFamily id="1639714" number="CN-102579345" title="Irbesartan liposome solid preparation"></PatentFamily><PatentFamily id="1677492" number="KR-2010055961" title="The new manufacturing method of the high blood pressure cure having the biphenyl group including tetrazole."></PatentFamily><PatentFamily id="1680993" number="EP-02065035" title="Pharmaceutical formulations containing irbesartan"></PatentFamily><PatentFamily id="168927" number="EP-00726072" title="Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor."></PatentFamily><PatentFamily id="1690686" number="KR-00482715" title="Pharmaceutical composition comprising irbesartan which provides tablets with high relative amount of active material and excellent wetting and disintegration properties"></PatentFamily><PatentFamily id="1697379" number="CN-101711747" title="Medicine applying preparation for treating high blood pressure"></PatentFamily><PatentFamily id="1703508" number="US-08080670" title="Process for the preparation of irbesartan"></PatentFamily><PatentFamily id="1709669" number="HR-P20100216" title="Solid pharmaceutical composition comprising irbesartan"></PatentFamily><PatentFamily id="1725190" number="WO-09925681" title="Method For Preparing Bromomethyl-Biphenyl Derivatives"></PatentFamily><PatentFamily id="1736336" number="WO-2006131632" title="Hydrates of alkaline-earth salts of irbesartan and the preparation thereof"></PatentFamily><PatentFamily id="1737693" number="WO-2008006712" title="Improvements relating to nanodispersions"></PatentFamily><PatentFamily id="1752113" number="WO-03066627" title="Deuterated spirocyclopentanimidazolinones and the use thereof in the treatment of cardiovascular diseases"></PatentFamily><PatentFamily id="1754901" number="WO-2006050923" title="Polymorph form of irbesartan"></PatentFamily><PatentFamily id="1756718" number="EP-00708103" title="Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative"></PatentFamily><PatentFamily id="1773917" number="WO-2009137543" title="Methods for breast cancer screening and treatment"></PatentFamily><PatentFamily id="178827" number="WO-2004072064" title="Synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspirol[4,4]-non-ene-4-one"></PatentFamily><PatentFamily id="1798948" number="WO-09906398" title="1,3-Oxazolinyl-biphenyl derivatives, preparation method and use as synthesis intermediates."></PatentFamily><PatentFamily id="1811443" number="WO-2008010008" title="Cardiovascular combinations using rennin-angiotensin inhibitors"></PatentFamily><PatentFamily id="1818153" number="CN-01199641" title="Compound irbesartan capsule for curing high blood pressure"></PatentFamily><PatentFamily id="1827218" number="WO-2008087397" title="Tosylate salts of irbesartan and their preparation and pharmaceutical compositions"></PatentFamily><PatentFamily id="1828894" number="WO-03035062" title="Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension"></PatentFamily><PatentFamily id="1847729" number="CN-101904847" title="Amlodipine nicotinate with synergetic blood pressure-lowering effect and treating composition of amlodipine nicotinate and sartan medicine"></PatentFamily><PatentFamily id="189390" number="UA-00069994" title="Method for correcting nephropathy in hypertension patients"></PatentFamily><PatentFamily id="1934939" number="IN-200801615" title="Improved process for preparation of irbesartan"></PatentFamily><PatentFamily id="1954086" number="WO-03030868" title="Flashmelt oral dosage formulation"></PatentFamily><PatentFamily id="1973482" number="JP-2010053048" title="Irbesartan containing pharmaceutical composition by which bitterness was relieved"></PatentFamily><PatentFamily id="1983949" number="EP-02194050" title="A new process for the preparation of irbesartan"></PatentFamily><PatentFamily id="2007246" number="CN-102335177" title="Oral solid pharmaceutical composition and preparation method thereof"></PatentFamily><PatentFamily id="2007775" number="IN-200700823" title="Efficient process for preparation of irbesartan intermediate"></PatentFamily><PatentFamily id="2031986" number="WO-2006125811" title="Oral dosage form comprising at least one active principle having a solubility that varies as a function of gastric ph conditions"></PatentFamily><PatentFamily id="204359" number="WO-2008018843" title="Process for producing useful salts form of biphenyl-tetrazole compounds"></PatentFamily><PatentFamily id="2050940" number="WO-2006050922" title="Process for the synthesis of tetrazoles"></PatentFamily><PatentFamily id="2066232" number="WO-2006023889" title="A method for preparing irbesartan and intermediates thereof"></PatentFamily><PatentFamily id="2107865" number="EP-01918288" title="A novel and improved process for the preparation of irbesartan, an angiotensin-ii receptor antagonist for the treatment of hypertension"></PatentFamily><PatentFamily id="2128336" number="IN-200600962" title="Novel process for preparing irbesartan involves reacting of 1-amino-cyclopentanecarboxylic acid with valeryl chloride in presence of base in a solvent to give 1-carboxy-1-pentanoylaminocyclopentane"></PatentFamily><PatentFamily id="2170201" number="WO-09965500" title="Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination."></PatentFamily><PatentFamily id="2177863" number="WO-2005075462" title="Coupling reactions useful in the preparation of (1H-tetrazol-5-yl)-biphenyl derivatives"></PatentFamily><PatentFamily id="2195389" number="CN-01732953" title="Dispersible tablet for treating hypertension"></PatentFamily><PatentFamily id="2200206" number="WO-09967236" title="Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same."></PatentFamily><PatentFamily id="2218781" number="WO-2008107799" title="Improved process for preparing irbesartan"></PatentFamily><PatentFamily id="2252926" number="WO-2006034631" title="Composition comprising amlodipine and angiotensin II receptor blocker"></PatentFamily><PatentFamily id="2279295" number="RU-02390338" title="Method of normalising functional reactivity of cardiovascular system in arterial hypertension, impaired glucose tolerance and abdominal obesity"></PatentFamily><PatentFamily id="2279363" number="RU-02392937" title="Method of decreasing blood microvesicles in crisis course of arterial hypertension"></PatentFamily><PatentFamily id="2285838" number="WO-2005007156" title="Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin ii receptor antagonist for the treatment of central nervous system damage"></PatentFamily><PatentFamily id="2290559" number="KR-2009030353" title="The pharmaceutical composition of the irbesartan in which the elution rate is improved."></PatentFamily><PatentFamily id="2301035" number="WO-2011001202" title="Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application"></PatentFamily><PatentFamily id="2301921" number="CN-102697754" title="Irbesartan capsule and preparation method thereof"></PatentFamily><PatentFamily id="2325833" number="WO-2005051928" title="Process for production of tetrazolyl compounds"></PatentFamily><PatentFamily id="2328972" number="US-08802707" title="Method of treating and/or preventing inflammatory diseases, including many autoimmune and neurological diseases, using drugs to modulate the VDR, and/or PPAR, and/or GCR and/or CB1 nuclear and GPCR receptors; in conjunction with antibiotics which target prokaryotic protein translation"></PatentFamily><PatentFamily id="2346601" number="WO-2008012852" title="Intermediate compounds for the preparation of angiotensin II antagonists"></PatentFamily><PatentFamily id="2350176" number="WO-09944613" title="Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin V receptors, even of V1A and V2 receptors."></PatentFamily><PatentFamily id="2351693" number="WO-2011010316" title="Pharmaceutical compositions of irbesartan"></PatentFamily><PatentFamily id="2360937" number="WO-2004062557" title="Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases"></PatentFamily><PatentFamily id="23640" number="WO-09955340" title="Pharmaceutical compositions containing in combination an arginine-vasopressin V1a antagonist and an angiotension II AT1 receptor antagonist."></PatentFamily><PatentFamily id="2377358" number="CN-102335157" title="Irbesartan sheet coating and preparation method and application thereof"></PatentFamily><PatentFamily id="2384698" number="IN-201003560" title="Improved process for preparation of irbesartan"></PatentFamily><PatentFamily id="2393063" number="CN-102743361" title="Irbesartan and hydrochlorothiazide capsule"></PatentFamily><PatentFamily id="2425477" number="CN-102793704" title="Medicinal composition of irbesartan and cyclopenthiazide and preparation method thereof"></PatentFamily><PatentFamily id="2434323" number="CN-202568932" title="Novel capsule loaded with irbesartan solid preparation and hydrochlorothiazide solid preparation"></PatentFamily><PatentFamily id="2456959" number="CN-102863398" title="Synthetic method for sartan drug intermediate and application of intermediate"></PatentFamily><PatentFamily id="2460218" number="CN-102875534" title="Synthesis method of irbesartan"></PatentFamily><PatentFamily id="2467644" number="CN-102898420" title="Synthetic route and preparation method of one kind of irbesartan"></PatentFamily><PatentFamily id="2493786" number="EP-01777224" title="A process for the preparation of angiotensin ii antagonistic compounds"></PatentFamily><PatentFamily id="253545" number="WO-2005025566" title="Oral pharmaceutical formulations containing the active ingredient irbesartan"></PatentFamily><PatentFamily id="2601995" number="CN-103040841" title="A one containing the irbesartan and hydrochlorothiazide pharmaceutical composition of"></PatentFamily><PatentFamily id="2622342" number="JP-05714652" title="Irbesartan containing pharmaceutical composition with favorable elution, and an orally disintegrating tablet"></PatentFamily><PatentFamily id="2625026" number="CN-103191126" title="Method for preparing irbesartan and hydrochlorothiazide tablets"></PatentFamily><PatentFamily id="2625074" number="CN-103191076" title="Preparing method is one of irbesartan tablet"></PatentFamily><PatentFamily id="2625079" number="CN-103191071" title="Irbesartan dispersible tablet and preparation method thereof"></PatentFamily><PatentFamily id="2635178" number="CN-103239457" title="A kind of irbesartan hydrochlorothiazide capsule and preparation method thereof"></PatentFamily><PatentFamily id="2636649" number="WO-2013171643" title="An improved process for preparation of irbesartan"></PatentFamily><PatentFamily id="2662380" number="CN-103356638" title="Set with irbesartan sheet a tablet capsule of hydrogen thiazole sheet"></PatentFamily><PatentFamily id="2692090" number="WO-2014035188" title="Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate"></PatentFamily><PatentFamily id="2692264" number="WO-2014035190" title="Pharmaceutical composite capsule formulation comprising irbesartan and HMG-CoA reductase inhibitor"></PatentFamily><PatentFamily id="2693625" number="CN-103497178" title="Co-non-forming substance"></PatentFamily><PatentFamily id="2698407" number="WO-2014041445" title="Compositions and methods for the treatment of hypertension and management of diabetic kidney disease"></PatentFamily><PatentFamily id="2703207" number="CN-103622970" title="A. hydrogen chlorine j irbesartan hydrochloride tablet and its preparation method"></PatentFamily><PatentFamily id="2709956" number="WO-2014051008" title="Deprotection method for tetrazole compound"></PatentFamily><PatentFamily id="2721406" number="CN-103721259" title="&lt;para&gt;Angiotensin II receptor blocker/thiazide diuretics/5-methyltetrahydrofolate pharmaceutical composition&lt;/para&gt;&lt;para&gt; &lt;/para&gt;"></PatentFamily><PatentFamily id="273420" number="WO-2007013101" title="Process for producing 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-l,3-diazaspiro[4.4]non-1-en-4-one"></PatentFamily><PatentFamily id="2738514" number="CN-103655579" title="Irbesartan hydrochlorothiazide pharmaceutical composition and preparation method thereof"></PatentFamily><PatentFamily id="2741714" number="CN-103787999" title="Synthesis method of irbesartan impurities"></PatentFamily><PatentFamily id="2749949" number="CN-103638019" title="New application of irbesartan in prevention and treatment of hepatitis B virus infection diseases"></PatentFamily><PatentFamily id="2761320" number="CN-103860511" title="A medicinal composition containing irbesartan and amlodipine besylate and preparation method thereof"></PatentFamily><PatentFamily id="2832677" number="CN-103989646" title="Irbesartan medicinal composition, as well preparation method and application thereof"></PatentFamily><PatentFamily id="2858686" number="JP-05686452" title="The tablet containing an irbesartan"></PatentFamily><PatentFamily id="286371" number="CN-01714794" title="Irbesartan hydrochlorothiazine dispersible tablet an dits preparing method"></PatentFamily><PatentFamily id="2901355" number="CN-104352632" title="Application of chinese arborvitae twig and folium artemisiae argyi capsule as a liver transporter inhibitor"></PatentFamily><PatentFamily id="290208" number="WO-2006013545" title="Pharmaceutical compositions of irbesartan"></PatentFamily><PatentFamily id="2919245" number="WO-2015054120" title="Ruthenium-catalyzed synthesis of biaryl compounds in water"></PatentFamily><PatentFamily id="2932158" number="CN-104478818" title="Synthesis method of 2-(1-hydrogen-4-tetrazol-4 '-methylbiphenyl"></PatentFamily><PatentFamily id="2934159" number="CN-104435312" title="A capsule used as intestinal transporter inhibitor"></PatentFamily><PatentFamily id="2954905" number="CN-104644642" title="A compound hydrogen irbesartan hydrochlorothiazide medicine composition and its preparation method"></PatentFamily><PatentFamily id="2959680" number="JP-05978335" title="Irbesartan containing pharmaceutical composition with favorable elution, and an orally disintegrating tablet"></PatentFamily><PatentFamily id="296417" number="CN-101912390" title="Medicinal composite containing irbesartan"></PatentFamily><PatentFamily id="2969654" number="CN-104706640" title="A medicinal composition containing irbesartan and its preparing technique"></PatentFamily><PatentFamily id="2972553" number="CN-104721191" title="Blood pressure reducing preparation"></PatentFamily><PatentFamily id="2985725" number="CN-104758283" title="An anti-hypertension preparation"></PatentFamily><PatentFamily id="3036917" number="JP-06238921" title="The tablet containing an irbesartan"></PatentFamily><PatentFamily id="3054991" number="KR-2015111644" title="The small molecule for the muscle injuries prevention by the microenvironment modulation."></PatentFamily><PatentFamily id="3069103" number="CN-105001209" title="Synthesis method of irbesartan"></PatentFamily><PatentFamily id="3074207" number="CN-105055362" title="Irbesartan hydrogen chlorine triazine thia-chip and preparation method thereof"></PatentFamily><PatentFamily id="3088506" number="CN-105078913" title="An irbesartan tablet and preparation method thereof"></PatentFamily><PatentFamily id="3106530" number="WO-2016006577" title="Pharmaceutical composition"></PatentFamily><PatentFamily id="3128109" number="CN-105250268" title="Irbesartan composition and use thereof in preparing medicine for treating acute kidney injury in application"></PatentFamily><PatentFamily id="3189866" number="CN-105534923" title="Method of preparing irbesartan superfine particles using supercritical anti-solvent technique"></PatentFamily><PatentFamily id="3217118" number="CN-105646353" title="Plug to co-amorphous"></PatentFamily><PatentFamily id="32406" number="WO-2006073376" title="Preparation of tetrazole derivative"></PatentFamily><PatentFamily id="3245208" number="WO-2016114725" title="A stable bilayer pharmaceutical tablet compositions comprising fixed dose of irbesartan and amlodipine"></PatentFamily><PatentFamily id="328535" number="WO-2005122699" title="An improved process for the preparation of N-substituted heterocyclic derivatives"></PatentFamily><PatentFamily id="3322870" number="CN-105859547" title="Medicine composition of irbesartan and application in biological medicine"></PatentFamily><PatentFamily id="3359892" number="WO-2016141476" title="Angiotensin receptor blocking drugs for use in cancer treatment"></PatentFamily><PatentFamily id="3405720" number="JP-06199922" title="The irbesartan containing tablet which chemical stability improved"></PatentFamily><PatentFamily id="3419893" number="JP-06151413" title="Irbesartan containing pharmaceutical composition with favorable elution, and an orally disintegrating tablet"></PatentFamily><PatentFamily id="3425432" number="CN-105998651" title="Traditional Chinese medicine composition for treating hypertension and preparation method thereof"></PatentFamily><PatentFamily id="3452192" number="CN-106083826" title="An irbesartan isomer and preperation method of intermediates thereof"></PatentFamily><PatentFamily id="3456539" number="CN-106117146" title="A method for preparing irbesartan"></PatentFamily><PatentFamily id="3457851" number="CN-106109471" title="A preparation method of improving irbesartan and hydrochlorothiazide tablet content uniformity of"></PatentFamily><PatentFamily id="3461072" number="CN-106146471" title="An irbesartan dual functional complex"></PatentFamily><PatentFamily id="346921" number="WO-2009046632" title="Pharmaceutical composition containing angiotensin II receptor blocker and B family vitamins and use thereof"></PatentFamily><PatentFamily id="3474886" number="JP-2016204306" title="Irbesartan containing tablet"></PatentFamily><PatentFamily id="3474887" number="JP-06445923" title="The preparation method of an irbesartan containing tablet"></PatentFamily><PatentFamily id="348304" number="WO-2008087399" title="Mesylate salts of irbesartan and their preparation and pharmaceutical compositions"></PatentFamily><PatentFamily id="3500849" number="JP-2017001973" title="Irbesartan containing tablet"></PatentFamily><PatentFamily id="351843" number="WO-09114679" title="Heterocyclic N-substituted derivatives, their preparation and the pharmaceutical compositions containing them."></PatentFamily><PatentFamily id="3533301" number="WO-2017017165" title="PDE4 Inhibitor for the treatment of diabetic nephropathy"></PatentFamily><PatentFamily id="3535553" number="IN-201502653" title="Pharmaceutical formulation used for treating hypertension and hypercholesterolemia, comprises independent irbesartan unit and independent 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor unit separated from each other in capsule"></PatentFamily><PatentFamily id="3535554" number="IN-201502652" title="Composite capsule formulation used to treat e.g. hypertension, comprises irbesartan unit, and 3-hydroxy-3-methyl-glutaryl-coenzyme a (hmg-coa) reductase inhibitor unit comprising hmg-coa reductase inhibitor and alkaline additive"></PatentFamily><PatentFamily id="3575155" number="JP-2017052752" title="The pharmaceutical composition containing an irbesartan, and its manufacturing method"></PatentFamily><PatentFamily id="3614311" number="CN-106562965" title="A medicine compound for curing renal hypertension"></PatentFamily><PatentFamily id="3621403" number="CN-106580992" title="A hydrochloric acid for treating hypertension of manidipine and irbesartan compound tablet and preparation method thereof"></PatentFamily><PatentFamily id="3634625" number="JP-06298435" title="The orally disintegrating tablet containing an angiotensin II receptor antagonist"></PatentFamily><PatentFamily id="3646120" number="JP-2017088598" title="Irbesartan containing pharmaceutical composition"></PatentFamily><PatentFamily id="3646174" number="JP-2017088505" title="Irbesartan containing pharmaceutical composition and its manufacturing method"></PatentFamily><PatentFamily id="3655290" number="CN-106706785" title="A method of irbesartan in hydrochlorothiazide tablet related substance with high performance liquid chromatography detection"></PatentFamily><PatentFamily id="366294" number="CN-101632644" title="Avapro dispersible tablet and preparation method thereof"></PatentFamily><PatentFamily id="3667171" number="JP-2017071560" title="The pharmaceutical composition containing an irbesartan, and its manufacturing method"></PatentFamily><PatentFamily id="3678537" number="CN-106727579" title="An irbesartan/rosuvastatin compound preparation and preparation method thereof"></PatentFamily><PatentFamily id="368666" number="KR-2009107952" title="Pharmaceutical preparation."></PatentFamily><PatentFamily id="373979" number="WO-2010042714" title="Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists"></PatentFamily><PatentFamily id="3745988" number="JP-2017132724" title="The mixing|blending orally disintegrating tablet containing an amlodipine containing coated particle"></PatentFamily><PatentFamily id="3750970" number="JP-2017137255" title="Amlodipine content blending lock|tablet of a coloring uncoated tablet"></PatentFamily><PatentFamily id="375832" number="WO-2010079405" title="An improved process for preparing 1-(pentanoylamino)cyclopentanecarboxylic acid"></PatentFamily><PatentFamily id="3759186" number="JP-2017141299" title="Irbesartan containing pharmaceutical composition with favorable elution, and an orally disintegrating tablet"></PatentFamily><PatentFamily id="3760402" number="CN-107033129" title="Synthesis method of irbesartan impurity"></PatentFamily><PatentFamily id="3761140" number="CN-107028912" title="A preparation method of irbesartan capsule"></PatentFamily><PatentFamily id="376529" number="WO-2011121592" title="Process for irbesartan substantially free of dimer impurity"></PatentFamily><PatentFamily id="3825207" number="CN-107235963" title="A method for efficiently preparing irbesartan impurity a of method"></PatentFamily><PatentFamily id="3841852" number="JP-06233911" title="The irbesartan containing tablet which chemical stability improved"></PatentFamily><PatentFamily id="3864737" number="JP-2017210435" title="The manufacturing method of an irbesartan and the amlodipine besylate combination tablet"></PatentFamily><PatentFamily id="3902134" number="CN-107468650" title="Irbesartan self-emulsifying soft capsule and preparation method thereof"></PatentFamily><PatentFamily id="3921771" number="JP-2018009032" title="The irbesartan containing tablet which chemical stability improved"></PatentFamily><PatentFamily id="3921984" number="JP-06321131" title="The dissolubility improvement method of amlodipine content blending lock|tablet"></PatentFamily><PatentFamily id="400335" number="WO-03050110" title="Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one"></PatentFamily><PatentFamily id="4007962" number="CN-107823427" title="A compound medical preparation for reducing fat"></PatentFamily><PatentFamily id="404636" number="WO-2007039117" title="A process for the preparation of sartan derivatives and intermediates useful in such process"></PatentFamily><PatentFamily id="4051672" number="WO-2018091967" title="Compositions for the treatment of hypertension"></PatentFamily><PatentFamily id="4054539" number="CN-107998129" title="Pharmaceutical composition for treating hypertension and preparation method thereof"></PatentFamily><PatentFamily id="4089218" number="JP-2018090617" title="The orally disintegrating tablet containing an angiotensin ii receptor antagonist"></PatentFamily><PatentFamily id="4107557" number="CN-108191836" title="Low static irbesartan raw materials of the preparation method"></PatentFamily><PatentFamily id="4123968" number="CN-108218841" title="A method for synthesizing high purity antihypertensive drug irbesartan"></PatentFamily><PatentFamily id="4128483" number="CN-108276389" title="A synthesis method of irbesartan"></PatentFamily><PatentFamily id="4169650" number="CN-108379271" title="A method for optimizing dissolution rate of irbesartan and hydrochlorothiazide tablet"></PatentFamily><PatentFamily id="4175083" number="CN-108434112" title="An irbesartan tablet and its preparation method"></PatentFamily><PatentFamily id="421436" number="WO-2008043167" title="Pharmaceutical compositions comprising intra- and extra-granular fractions"></PatentFamily><PatentFamily id="4226051" number="CN-108578404" title="Medicinal composition containing irbesartan and amlodipine and preparation method thereof"></PatentFamily><PatentFamily id="4242308" number="CN-108653581" title="Radix paeoniae alba, dendrobium officinale and irbesartan preparation method medicine for treating hypertension"></PatentFamily><PatentFamily id="4250865" number="JP-2018168185" title="Irbesartan containing pharmaceutical composition with favorable elution, and an orally disintegrating tablet"></PatentFamily><PatentFamily id="4266936" number="CN-108743955" title="A subcutaneous implant bar for essential hypertension elastomer"></PatentFamily><PatentFamily id="4288827" number="CN-108840860" title="Method for one-pot method of preparing irbesartan"></PatentFamily><PatentFamily id="4355577" number="CN-109157527" title="Irbesartan capsule and preparation method thereof"></PatentFamily><PatentFamily id="4393522" number="CN-109295216" title="Predicting hypertension individual drug effect of snp site and detection kit"></PatentFamily><PatentFamily id="443204" number="KR-2009052944" title="The pharmaceutical composition containing irbesartan."></PatentFamily><PatentFamily id="448004" number="CN-102319250" title="Irbesartan hydrochlorothiazide medicine composition and preparation method"></PatentFamily><PatentFamily id="453827" number="IN-200801276" title="Improved process for preparation of irbesartan"></PatentFamily><PatentFamily id="49150" number="CN-101781287" title="Irbesartan hydrobromide and preparation method thereof"></PatentFamily><PatentFamily id="493387" number="JP-05296456" title="Irbesartan containing pharmaceutical composition with favorable elution, and an orally disintegrating tablet"></PatentFamily><PatentFamily id="509583" number="CN-101648945" title="A method for synthesizing an important intermediate of irbesartan"></PatentFamily><PatentFamily id="517818" number="WO-2008026012" title="Novel compositions and methods"></PatentFamily><PatentFamily id="52019" number="WO-2007080074" title="Solid pharmaceutical composition comprising irbesartan"></PatentFamily><PatentFamily id="538665" number="EP-00752249" title="Use of an angiotensin II antagonist and a benzofuran derivative having antiarithmic activity for the manufacture of a medicament for the treatment of cardiovascular disorders."></PatentFamily><PatentFamily id="588114" number="CN-101481374" title="Removing three benzyl method of 1-benzyl-5-(1, 1'- biphenylyl-2) -1h-tetrazoles compound"></PatentFamily><PatentFamily id="622482" number="WO-2004007482" title="Novel synthesis of irbesartan"></PatentFamily><PatentFamily id="624010" number="WO-2005118166" title="Pharmaceutical composition containing irbesartan"></PatentFamily><PatentFamily id="642202" number="CZ-200500221" title="Process for preparing trityl irbesartan and use thereof in irbesartan synthesis process"></PatentFamily><PatentFamily id="642421" number="WO-2007115990" title="Process for the preparation of pure irbesartan"></PatentFamily><PatentFamily id="66929" number="WO-2007122508" title="An improved process for the preparation of irbesartan"></PatentFamily><PatentFamily id="686484" number="EP-00532410" title="N-substituted heterocyclic derivatives as angiotensin II inhibitors."></PatentFamily><PatentFamily id="698309" number="WO-2006036054" title="Treatment of prevention of unscheduled bleeding in women on progestogen containing medication"></PatentFamily><PatentFamily id="700310" number="WO-2007054965" title="Process for preparation of tetrazoles from aromatic cyano derivatives"></PatentFamily><PatentFamily id="715067" number="KR-00963520" title="The improved manufacturing method of irbesartan."></PatentFamily><PatentFamily id="715606" number="WO-2004065383" title="Novel synthesis of irbesartan"></PatentFamily><PatentFamily id="735848" number="WO-2008027385" title="Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole"></PatentFamily><PatentFamily id="744931" number="WO-2011141783" title="Pharmaceutical composition comprising irbesartan"></PatentFamily><PatentFamily id="762371" number="WO-09905119" title="Process For The Preparation Of 1,3-Diaza-Spiro (4.4) Non-1-En-4-One Derivatives And 1-Cyano-1-Acylamino-Cyclopentane Intermediates"></PatentFamily><PatentFamily id="786936" number="WO-2009072137" title="Process for pure irbesartan"></PatentFamily><PatentFamily id="789486" number="WO-00016773" title="Pharmaceutical composition containing an angiotensin II AT1 receptor antagonist and an antiplatelet agent"></PatentFamily><PatentFamily id="798620" number="RU-02390336" title="Method of normalising functional reactivity of cardiovascular system in arterial hypertension and impaired glucose tolerance"></PatentFamily><PatentFamily id="819872" number="WO-2011061996" title="Process for production of biphenyl derivative"></PatentFamily><PatentFamily id="848424" number="WO-2007093168" title="Rapid release irbesartan-containing pharmaceutical composition"></PatentFamily><PatentFamily id="870053" number="WO-2005021535" title="A method of removing the triphenylmethane protecting group"></PatentFamily><PatentFamily id="898715" number="IN-200802210" title="Novel process for preparation of irbesartan"></PatentFamily><PatentFamily id="907977" number="US-05541209" title="Method of treating or preventing cardiac arrhythemia emploiying an N-substituted heterocyclic derivative."></PatentFamily><PatentFamily id="910383" number="WO-09717064" title="Stable Freeze-Dried Pharmaceutical Formulation"></PatentFamily><PatentFamily id="910483" number="WO-09905118" title="Process For The Preparation Of Imidazolones"></PatentFamily><PatentFamily id="920704" number="US-20060211866" title="Process for the preparation of angiotensin receptor blockers and intermediates thereof"></PatentFamily><PatentFamily id="922220" number="WO-2007049293" title="An improved process for preparation of irbesartan"></PatentFamily><PatentFamily id="962171" number="WO-2009149734" title="Process for the preparation of irbesartan and intermediate products"></PatentFamily><PatentFamily id="965044" number="WO-2010116380" title="A one pot process for preparing 2-butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4]non-1-en-4-one (irbesartan)"></PatentFamily><PatentFamily id="985512" number="WO-09905120" title="Process For The Preparation Of 1,3-Diaza-Spiro (4.4) Non-1-En-4-One Derivatives And 1-Cyano-1-Acylaminocyclopentane Intermediates"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>65</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>27</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>15</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>80</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>107</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>11</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohara Pharmaceutical Co Ltd" id="1000882"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jubilant Life Sciences Ltd" id="1003756"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="East China University of Science &amp; Technology" id="1004888"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Hengrui Medicine Co Ltd" id="1006925"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BC Cancer Agency" id="1007766"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lunan Pharmaceutical Co Ltd" id="1009275"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>25</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>25</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohara Yakuhin Kogyo Kk" id="1010402"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Divis Laboratories Ltd" id="1015911"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Hisun Pharmaceutical Co Ltd" id="1019688"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BDD/CCDRD Group" id="1020190"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Calyx Chemicals &amp; Pharmaceuticals Private Ltd" id="1021615"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Algry Quimica S L" id="1021626"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsubishi Chemical Holdings Corp" id="1022450"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharma Holdings Inc" id="1022451"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd" id="1023252"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yangtze River Pharmaceutical Group" id="1024536"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intas Pharmaceuticals Ltd" id="1028220"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Micro Labs Ltd" id="1028350"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Pharmaceutical Group Co Ltd" id="1030330"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Tianyu Pharmaceutical Co Ltd" id="1030351"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Farmaprojects SA" id="1030694"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen Ausa Pharmed Co Ltd" id="1035805"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eurapharm Inc" id="1037245"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sims Srl - Società Italiana Medicinali     Scandicci" id="1037414"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Huaanfo Biomedical Research Centre Inc" id="1039287"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Otsuka Holdings Co Ltd" id="1040632"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rainbow Engineering Services" id="1040967"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Pui'S Pharmaceutical Factory Ltd" id="1041797"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui Globe Pharmaceutical Co Ltd" id="1047041"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing SL Pharmaceutical Co Ltd" id="1047948"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ore Pharmaceutical Holdings Inc" id="1050337"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yiling Pharmaceutical Group" id="1056617"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Meilan Smith Kline Pharmaceutical" id="1056717"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ctx Life Sciences Pvt Ltd" id="1057434"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ulkar Holding" id="1057755"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IOTA NanoSolutions Ltd" id="1058066"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanmi Holdings Co Ltd" id="1060189"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Invent Farma ehf" id="1063377"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Krisani Biosciences (P) Ltd" id="1066295"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Jinrui Pharmaceutical Co Ltd" id="1066348"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhuhai Rundu Pharmaceutical Co Ltd" id="1066809"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Defeng Pharmaceutical &amp; Chemical Co Ltd" id="1068481"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ogene Systems (I) Pvt Ltd" id="1068482"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Zhengkuan Medicine Technology Co Ltd" id="1068547"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Zhengke Pharmaceutical Co Ltd" id="1068599"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heilongjiang Fuhe Huaxing Pharmaceutical Group Co Ltd" id="1069532"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinan Limin Pharmaceutical Co Ltd" id="1069623"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hefei University of Technology" id="1070075"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xuchang Hengsheng Pharmaceutical Co Ltd" id="1070289"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanxi Weiqida Pharmaceutical Co., Ltd" id="1071581"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Hongrui Pharmaceutical Technology Co Ltd" id="1071715"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Langke Biotech Co Ltd" id="1072651"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Northeast Pharmaceutical Group Co Ltd" id="1073084"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sino Biopharmaceutical Ltd" id="1073089"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gaitianli Co Ltd" id="1073532"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Jiberer Pharmaceutical Company Ltd" id="1074825"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Connaught Pharmaceutical Co Ltd" id="1075962"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Xinyi Jiahua Pharmaceutical Co Ltd" id="1076478"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qidong Dongyue Pharmaceutical Co Ltd" id="1077724"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Henan Huashang Pharmaceutical Co Ltd" id="1079463"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heilongjiang ZBD Pharmaceutical Co Ltd" id="1082498"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The George Institute for Global Health" id="1084051"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Fubang Pharmaceutical Co Ltd" id="1084502"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ShanDong Tianlu Pharmaceutical Co Ltd" id="1085252"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Sunan Pharmaceutical Industries Limited" id="1087815"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ilko Ilac Sanayi Ve Ticaret As" id="1098081"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jilin Provincial Science &amp; Technology Department" id="1099175"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebei Longhai Yaoye Co Ltd" id="1101711"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangdong Yihao Pharmaceutical Co., Ltd." id="1102497"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Zhongji Medical Technology Co Ltd" id="1102750"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chicago Discovery Solutions Llc" id="1108029"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Bangde Pharmaceutical Co Ltd" id="1108714"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harbin Shengji Pharmaceutical Co Ltd" id="1108717"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CarysBio Holdings Ltd" id="1108952"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cheer Fine Pharmaceutical (Anhui) Co Ltd" id="1111189"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhengzhou Taifeng Pharmaceutical Co Ltd" id="1124470"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Avadel Pharmaceuticals plc" id="1128249"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohara Pharmaceutical Industry Co., Ltd." id="1141039"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chengdu Xianxianxian Biotechnology Co Ltd" id="1144950"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amruta Pharma" id="1144954"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alliance Medical Group" id="1148001"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huayi Pharmaceutical Technology (Anhui) Co Ltd" id="1152315"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SENTAN Pharma Inc" id="1153441"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jilin Xiuzheng Pharmaceutical Group Stock Co., Ltd" id="1174586"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co. Ltd." id="1175177"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Fluoride Biological Testing Technology Co., Ltd." id="1176569"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ningbo Ajcore Biotechnology Co Ltd" id="1181478"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Military Sciences" id="14168"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Macleod Pharm Inc" id="14380"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Commissariat a l`Energie Atomique" id="15529"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daito Pharmaceutical Co Ltd" id="15610"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Il Dong Pharmaceutical Co Ltd" id="17101"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Krka dd Novo Mesto" id="17690"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sawai Pharmaceutical Co Ltd" id="19683"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shionogi &amp; Co Ltd" id="19898"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Unilever" id="20470"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Sydney" id="20681"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>23</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>23</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharmaceutical University" id="21231"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Liverpool" id="21242"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daito KK" id="21677"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="HanAll Biopharma Co Ltd" id="22230"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LG Chem Ltd" id="22235"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmascience Inc" id="24846"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyushu University" id="25556"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dinamite Dipharma SpA" id="26954"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wockhardt Ltd" id="27614"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orexo AB" id="27664"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tecnimede-Sociedade Technico-Medicinal SA" id="27976"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyungpook National University" id="28011"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Simon Fraser University" id="28912"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zydus-Cadila Group" id="29062"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Livzon Pharmaceutical Group Inc" id="29608"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alembic Ltd" id="29955"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cadila Pharmaceuticals Ltd" id="30025"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pantarhei Bioscience BV" id="30194"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aurobindo Pharma Ltd" id="30215"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medichem SA" id="30595"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Honeywell International Inc" id="30855"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nipro Corp" id="30972"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing University of Chemical Technology" id="31722"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin University" id="CM27908"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>